Table 4. Distribution of baseline characteristics stratified by pretreatment IBIL.
| Baseline characteristics | Training cohort | Validation cohort | ||||
|---|---|---|---|---|---|---|
| Low IBIL | High IBIL | P | Low IBIL | High IBIL | P | |
| Age (years) | 64 (56–73) | 64 (54–73) | 0.180 | 64 (56–75) | 64 (56–73) | 0.098 |
| Sex (male) | 75 (33.19) | 27 (33.33) | 0.981 | 95 (41.48) | 30 (30.61) | 0.064 |
| Smoking | 39 (17.26) | 19 (23.46) | 0.221 | 49 (21.40) | 25 (25.51) | 0.415 |
| ECOG PS | ||||||
| 0–1 | 142 (62.83) | 55 (67.90) | 0.414 | 180 (78.60) | 86 (87.76) | 0.052 |
| 2–3 | 84 (37.17) | 26 (32.10) | 49 (21.40) | 12 (12.24) | ||
| Histological type | ||||||
| Adenocarcinoma | 145 (64.16) | 48 (59.26) | 0.434 | 151 (65.94) | 62 (63.27) | 0.642 |
| Non-adenocarcinoma | 81 (35.84) | 33 (40.74) | 78 (34.06) | 36 (36.73) | ||
| TNM stage (I/II/III) | 78/78/70 | 21/28/32 | 0.263 | 67/70/92 | 26/29/43 | 0.807 |
| pT stage (1/2/3/4) | 50/32/131/13 | 10/12/50/9 | 0.141 | 52/32/116/29 | 20/27/44/7 | 0.023 |
| pN stage (0/1/2/3) | 98/73/32/23 | 30/20/22/9 | 0.058 | 84/84/39/22 | 47/29/18/4 | 0.117 |
| chemotherapy | 144 (63.72) | 43 (53.09) | 0.093 | 149 (65.07) | 26 (26.53) | <0.001 |
| CEA (ng/mL) | ||||||
| <5 | 148 (65.49) | 52 (64.20) | 0.835 | 140 (61.14) | 54 (55.10) | 0.309 |
| ≥5 | 78 (34.51) | 29 (35.80) | 89 (38.86) | 44 (44.90) | ||
ECOG PS, Eastern Cooperative Oncology Group performance status; IBIL, indirect bilirubin.
All data were analyzed using χ2 test or Mann-Whitney U test.
Values are expressed as medians (interquartile range) or frequencies and percentages.